Sup /fit/, for anons with enough interest in molecular pharmacology of non-androgen receptors, Bad Luck Bryan dropped some weird new farnesylcysteine serum for skin anti-aging. Inhibiting the enzyme that endogenously processes this moiety had positive results specifically in body weight with Hutchinson–Gilford progeria syndrome...>Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome>https://pmc.ncbi.nlm.nih.gov/articles/PMC3478615/>Twenty-five patients with HGPS received the farnesyltransferase inhibitor lonafarnib for a minimum of 2 y. Primary outcome success was predefined as a 50% increase over pretherapy in estimated annual rate of weight gain, or change from pretherapy weight loss to statistically significant on-study weight gain. Nine patients experienced a ≥50% increase, six experienced a ≥50% decrease, and 10 remained stable with respect to rate of weight gain.This stuff is a little cost-prohibitive unless you happen to have Bad Luck Bryan-tier resources.>For a 30-capsule supply of 50mg lonafarnib (Zokinvy) capsules, the price is approximately $27,599 when using a discount card.However, there is also an O.G. farnesyltransferase inhibitor, Clavaric acid, found in a hillbilly mushroom called Hypholoma lateritium that Wikipedia says "is sometimes considered edible."Thoughts on Bad Luck Bryan's new skin serum, FTIs, or more abstruse anti-aging interventions than he knows about generally?
>Nature Communications, 16, Article number: 9152 (2025) Review Article Open access Published: 15 October 2025>The geroprotective potential of chalcones>https://www.nature.com/articles/s41467-025-64167-7
